Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

Maura Pugliatti; Hans Peter Hartung; Celia Oreja-Guevara; Carlo Pozzilli; Laura Airas; Mona Alkhawajah; Nikolaos Grigoriadis; Melinda Magyari; Bart Van Wijmeersch; Magd Zakaria; Ralf Linker; Andrew Chan; Patrick Vermersch; Thomas Berger

doi:10.3389/fimmu.2022.1045101

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

Maura Pugliatti, Hans Peter Hartung^*, Celia Oreja-Guevara, Carlo Pozzilli, Laura Airas, Mona Alkhawajah, Nikolaos Grigoriadis, Melinda Magyari, Bart Van Wijmeersch, Magd Zakaria, Ralf Linker, Andrew Chan, Patrick Vermersch, Thomas Berger

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Review › peer review

6 Citationer (Scopus)

8 Downloads (Pure)

Abstract

It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

Originalsprog	Engelsk
Artikelnummer	1045101
Tidsskrift	Frontiers in Immunology
Vol/bind	13
Antal sider	8
ISSN	1664-3224
DOI	https://doi.org/10.3389/fimmu.2022.1045101
Status	Udgivet - 2022

Bibliografisk note

Funding Information:
The authors acknowledge the financial and operational support of the ParadigMS Foundation that made it possible to produce this article. ParadigMS activities are co-funded by Sanofi, Roche and Merck.

Publisher Copyright:
Copyright © 2022 Pugliatti, Hartung, Oreja-Guevara, Pozzilli, Airas, Alkhawajah, Grigoriadis, Magyari, Van Wijmeersch, Zakaria, Linker, Chan, Vermersch and Berger.

Adgang til dokumentet

10.3389/fimmu.2022.1045101Licens: CC BY

FulltextForlagets udgivne version, 636 KBLicens: CC BY

Citationsformater

Pugliatti, M., Hartung, H. P., Oreja-Guevara, C., Pozzilli, C., Airas, L., Alkhawajah, M., Grigoriadis, N., Magyari, M., Van Wijmeersch, B., Zakaria, M., Linker, R., Chan, A., Vermersch, P., & Berger, T. (2022). Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. Frontiers in Immunology, 13, Artikel 1045101. https://doi.org/10.3389/fimmu.2022.1045101

@article{5c529ad4dd0145329aa180c888289130,

title = "Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in",

abstract = "It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.",

keywords = "adverse events, COVID-19, disease modifying therapies, immune response, multiple sclerosis, SARS-CoV-2, vaccines",

author = "Maura Pugliatti and Hartung, {Hans Peter} and Celia Oreja-Guevara and Carlo Pozzilli and Laura Airas and Mona Alkhawajah and Nikolaos Grigoriadis and Melinda Magyari and {Van Wijmeersch}, Bart and Magd Zakaria and Ralf Linker and Andrew Chan and Patrick Vermersch and Thomas Berger",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Pugliatti, Hartung, Oreja-Guevara, Pozzilli, Airas, Alkhawajah, Grigoriadis, Magyari, Van Wijmeersch, Zakaria, Linker, Chan, Vermersch and Berger.",

year = "2022",

doi = "10.3389/fimmu.2022.1045101",

language = "English",

volume = "13",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Anti-SARS-CoV-2 vaccination in people with multiple sclerosis

T2 - Lessons learnt a year in

AU - Pugliatti, Maura

AU - Hartung, Hans Peter

AU - Oreja-Guevara, Celia

AU - Pozzilli, Carlo

AU - Airas, Laura

AU - Alkhawajah, Mona

AU - Grigoriadis, Nikolaos

AU - Magyari, Melinda

AU - Van Wijmeersch, Bart

AU - Zakaria, Magd

AU - Linker, Ralf

AU - Chan, Andrew

AU - Vermersch, Patrick

AU - Berger, Thomas

PY - 2022

Y1 - 2022

N2 - It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

AB - It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

KW - adverse events

KW - COVID-19

KW - disease modifying therapies

KW - immune response

KW - multiple sclerosis

KW - SARS-CoV-2

KW - vaccines

U2 - 10.3389/fimmu.2022.1045101

DO - 10.3389/fimmu.2022.1045101

M3 - Review

C2 - 36325318

AN - SCOPUS:85140995489

SN - 1664-3224

VL - 13

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 1045101

ER -